Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis	Novartis	Ongoing	ofatumumab	3	COMB157G2301	King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
International, randomized, open label study to compare the safety and efficacy of lixisenatide vs sulfonylurea on top of basal insulin treatment in Type 2 Diabetes Mellitus subjects who elect to fast during Ramadan	Sanofi	Terminated	Lixisenatide	3	LPS14410	King Khalid University Hospital (Riyadh)
"Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation"	Novartis	Ongoing	deferasirox	2	CICL670FIC05	King Abdulaziz University Hospital (Jeddah), Hereditary Blood Disease Center (al ahsa), King Abdulaziz Medical City NG (Riyadh)
A Phase II Study to examine the efficacy and safety of a new drug called Sevuparin on resolution of painful vaso-occlusive crisis in patients with sickle-cell disease.	Dilaforette AB	Ongoing	Sevuparin	2	TVOC01	King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), Qatif Central Hospital
Multicenter Inetrnational neoadjuvant randomized double-blind trial comparing fulvestrant to a combination of fulvestrant and palcociclib in patients with operable luminal breast cancer responding to fulvestrant	ICR Group - International Cancer Research group	Ongoing	palbociclib fulvestrant	3	ICRG 1201	King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah)
A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF USING TOCILIZUMAB (TCZ) FOR CONFIRMED RHEUMATOID ARTHRITIS (RA) PATIENTS IN CLINICAL PRACTICE	Roche	Ongoing	tocilizumab	4	ML299336	King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh)
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients with MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age	Shire Human Genetic Therapies, Inc	Ongoing	Elaprase	4	SHPELA401	King Faisal Specialist Hospital and Research Center (Riyadh)
"CLCZ696B2401-TRANSITION (A multicenter, randomized, open label, parallel group studycomparing pre-discharge and posT-discharge tReatmentinitiation with LCZ696 in heArt failure patieNtS withreduced ejectIon-fracTion hospItalized for an acutedecOmpensation eveNt (ADHF)"	Novartis	Ongoing	Entresto (SACUBITRIL, VALSARTAN)	4	CZ696B2401	Saud Al-Babtain Cardiac Center (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah), King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh)
"A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition tothe Paliperidone Palmitate 3-Month Formulation in Patients with SchizophreniaPreviously Stabilized on the Paliperidone Palmitate 1-Month Formulation"	Janssen-Cilag International NV	Ongoing	paliperidone	3	R092670SCH3015	Jeddah psychiatric hospital, Al-Amal Complex for mental health (Dammam)
"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial withan open-label extension that investigates the effect of the addition of dulaglutide (0.75 and1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baselinein hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus"	Eli Lilly	Ongoing	Dulaglutide 0.75 /1.5 mg	3	H9X-MC-GBGC	King Khalid University Hospital (Riyadh), International Medical Center (Jeddah)